These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29110353)

  • 1. Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia.
    Caravaggio F; Fervaha G; Iwata Y; Plitman E; Chung JK; Nakajima S; Mar W; Gerretsen P; Kim J; Chakravarty MM; Mulsant B; Pollock B; Mamo D; Remington G; Graff-Guerrero A
    Int J Geriatr Psychiatry; 2018 Mar; 33(3):523-530. PubMed ID: 29110353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.
    Fervaha G; Caravaggio F; Mamo DC; Mulsant BH; Pollock BG; Nakajima S; Gerretsen P; Rajji TK; Mar W; Iwata Y; Plitman E; Chung JK; Remington G; Graff-Guerrero A
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3803-3813. PubMed ID: 27557949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
    Iwata Y; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Plitman E; Chung JK; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Mamo DC; Graff-Guerrero A
    J Clin Psychiatry; 2016 Dec; 77(12):e1557-e1563. PubMed ID: 28086010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C]raclopride.
    Kim JH; Son YD; Kim HK; Lee SY; Cho SE; Kim YB; Cho ZH
    J Clin Psychopharmacol; 2011 Aug; 31(4):507-11. PubMed ID: 21694619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response.
    Peciña M; Sikora M; Avery ET; Heffernan J; Peciña S; Mickey BJ; Zubieta JK
    Eur Neuropsychopharmacol; 2017 Oct; 27(10):977-986. PubMed ID: 28870407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apathy is not associated with reduced ventral striatal volume in patients with schizophrenia.
    Burrer A; Caravaggio F; Manoliu A; Plitman E; Gütter K; Habermeyer B; Stämpfli P; Abivardi A; Schmidt A; Borgwardt S; Chakravarty M; Lepage M; Dagher A; Graff-Guerrero A; Seifritz E; Kaiser S; Kirschner M
    Schizophr Res; 2020 Sep; 223():279-288. PubMed ID: 32928618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between regional gray matter volumes and dopamine D
    Kurose S; Kubota M; Takahata K; Yamamoto Y; Fujiwara H; Kimura Y; Ito H; Takeuchi H; Mimura M; Suhara T; Higuchi M
    Hum Brain Mapp; 2021 Aug; 42(12):4048-4058. PubMed ID: 34014611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D2 heteroreceptor complexes and their receptor-receptor interactions in ventral striatum: novel targets for antipsychotic drugs.
    Fuxe K; Borroto-Escuela DO; Tarakanov AO; Romero-Fernandez W; Ferraro L; Tanganelli S; Perez-Alea M; Di Palma M; Agnati LF
    Prog Brain Res; 2014; 211():113-39. PubMed ID: 24968778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures.
    Wolf DH; Satterthwaite TD; Kantrowitz JJ; Katchmar N; Vandekar L; Elliott MA; Ruparel K
    Schizophr Bull; 2014 Nov; 40(6):1328-37. PubMed ID: 24657876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas.
    Vernaleken I; Janouschek H; Raptis M; Hellmann S; Veselinovic T; Bröcheler A; Boy C; Cumming P; Hiemke C; Rösch F; Schäfer WM; Gründer G
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):951-60. PubMed ID: 20392299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.
    Kegeles LS; Slifstein M; Xu X; Urban N; Thompson JL; Moadel T; Harkavy-Friedman JM; Gil R; Laruelle M; Abi-Dargham A
    Biol Psychiatry; 2010 Oct; 68(7):634-41. PubMed ID: 20673873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extrastriatal dopamine D
    Nørbak-Emig H; Pinborg LH; Raghava JM; Svarer C; Baaré WFC; Allerup P; Friberg L; Rostrup E; Glenthøj B; Ebdrup BH
    World J Biol Psychiatry; 2017 Oct; 18(7):539-549. PubMed ID: 27782768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.
    Suzuki T; Graff-Guerrero A; Uchida H; Remington G; Caravaggio F; Borlido C; Pollock B; Mulsant B; Deluca V; Ismail Z; Mamo D
    Psychopharmacology (Berl); 2013 Jul; 228(1):43-51. PubMed ID: 23417515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
    Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
    J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effort-Based Reinforcement Processing and Functional Connectivity Underlying Amotivation in Medicated Patients with Depression and Schizophrenia.
    Park IH; Lee BC; Kim JJ; Kim JI; Koo MS
    J Neurosci; 2017 Apr; 37(16):4370-4380. PubMed ID: 28283562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.